BACKGROUND: Recurrent medulloblastoma has long been considered universally fatal. In spite of attempts to improve its treatment, only rarely have long term survivors been documented in the world's medical literature. Although the treatment of primary medulloblastoma is well established and includes surgical excision, postsurgical irradiation, and, more recently, chemotherapy, there is no established treatment for its recurrence. Current guidelines dictate the experimental use of chemotherapy, and there have been some encouraging results; yet no increase in long term survival has been documented. METHODS: This article presents a case of cured recurrent medulloblastoma in which the only intervention at the time of recurrence was surgical excision. In addition, a review of the literature is presented, which evaluates chemotherapeutic trials involving cases of recurrent medulloblastoma. RESULTS: The authors were surprised to find that the longest survivors of multiple trials had undergone reoperation at the time of recurrence. The authors' case, as well as cases described in the literature, point to a valid treatment alternative largely ignored in the management of recurrent medulloblastoma. CONCLUSIONS: Reoperation of recurrent brain tumors has received surprisingly little attention in the medical literature. Yet, as this case and a review of the literature demonstrate, this is a useful intervention.
BACKGROUND: Recurrent medulloblastoma has long been considered universally fatal. In spite of attempts to improve its treatment, only rarely have long term survivors been documented in the world's medical literature. Although the treatment of primary medulloblastoma is well established and includes surgical excision, postsurgical irradiation, and, more recently, chemotherapy, there is no established treatment for its recurrence. Current guidelines dictate the experimental use of chemotherapy, and there have been some encouraging results; yet no increase in long term survival has been documented. METHODS: This article presents a case of cured recurrent medulloblastoma in which the only intervention at the time of recurrence was surgical excision. In addition, a review of the literature is presented, which evaluates chemotherapeutic trials involving cases of recurrent medulloblastoma. RESULTS: The authors were surprised to find that the longest survivors of multiple trials had undergone reoperation at the time of recurrence. The authors' case, as well as cases described in the literature, point to a valid treatment alternative largely ignored in the management of recurrent medulloblastoma. CONCLUSIONS: Reoperation of recurrent brain tumors has received surprisingly little attention in the medical literature. Yet, as this case and a review of the literature demonstrate, this is a useful intervention.
Authors: He Yue; Wang Ling; Ou Yibo; Wang Sheng; Tang Sicheng; Chen Jincao; Guo Dongsheng Journal: Childs Nerv Syst Date: 2018-06-23 Impact factor: 1.475
Authors: Mariam S Aboian; Cassie N Kline; Yi Li; David A Solomon; Erin Felton; Anu Banerjee; Steve E Braunstein; Sabine Mueller; William P Dillon; Soonmee Cha Journal: Neurooncol Pract Date: 2018-02-17
Authors: Abhimanyu Ghose; John C Morris; John C Breneman; James Essell; Jiang Wang; Sadia Benzaquen Journal: J Investig Med High Impact Case Rep Date: 2014-04-17
Authors: Rahul Kumar; Kyle S Smith; Maximilian Deng; Colt Terhune; Giles W Robinson; Brent A Orr; Anthony P Y Liu; Tong Lin; Catherine A Billups; Murali Chintagumpala; Daniel C Bowers; Timothy E Hassall; Jordan R Hansford; Dong Anh Khuong-Quang; John R Crawford; Anne E Bendel; Sridharan Gururangan; Kristin Schroeder; Eric Bouffet; Ute Bartels; Michael J Fisher; Richard Cohn; Sonia Partap; Stewart J Kellie; Geoffrey McCowage; Arnold C Paulino; Stefan Rutkowski; Gudrun Fleischhack; Girish Dhall; Laura J Klesse; Sarah Leary; Javad Nazarian; Marcel Kool; Pieter Wesseling; Marina Ryzhova; Olga Zheludkova; Andrey V Golanov; Roger E McLendon; Roger J Packer; Christopher Dunham; Juliette Hukin; Maryam Fouladi; Claudia C Faria; Jose Pimentel; Andrew W Walter; Nada Jabado; Yoon-Jae Cho; Sebastien Perreault; Sidney E Croul; Michal Zapotocky; Cynthia Hawkins; Uri Tabori; Michael D Taylor; Stefan M Pfister; Paul Klimo; Frederick A Boop; David W Ellison; Thomas E Merchant; Arzu Onar-Thomas; Andrey Korshunov; David T W Jones; Amar Gajjar; Vijay Ramaswamy; Paul A Northcott Journal: J Clin Oncol Date: 2021-01-27 Impact factor: 44.544
Authors: Christine Gaab; Jonas E Adolph; Stephan Tippelt; Ruth Mikasch; Denise Obrecht; Martin Mynarek; Stefan Rutkowski; Stefan M Pfister; Till Milde; Olaf Witt; Brigitte Bison; Monika Warmuth-Metz; Rolf-Dieter Kortmann; Stefan Dietzsch; Torsten Pietsch; Beate Timmermann; Ronald Sträter; Udo Bode; Andreas Faldum; Robert Kwiecien; Gudrun Fleischhack Journal: Cancers (Basel) Date: 2022-01-18 Impact factor: 6.639
Authors: David I Sandberg; Michael Rytting; Wafik Zaky; Marcia Kerr; Leena Ketonen; Uma Kundu; Bartlett D Moore; Grace Yang; Ping Hou; Clark Sitton; Laurence J Cooper; Vidya Gopalakrishnan; Dean A Lee; Peter F Thall; Soumen Khatua Journal: J Neurooncol Date: 2015-08-09 Impact factor: 4.130
Authors: Antonio Ruggiero; Anna Ariano; Silvia Triarico; Michele Antonio Capozza; Alberto Romano; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà Journal: Drugs Context Date: 2020-06-02